Clinical trials are central to the development of novel and life-saving cancer detection, prevention or treatment strategies. The conduct of trials supported by the National Cancer Institute (NCI) involves a complex system of designing, reviewing and initiating studies. To manage this system, the NCI has designed a new network to improve the speed and efficiency of cancer clinical trials.
The National Clinical Trials Network (NCTN) — which will focus on early and late stage clinical trials for adults with cancer — will consist of fewer but larger groups of investigators and will distribute resources in a more effective way. The University of Chicago Medicine Comprehensive Cancer Center has received a five-year, $3.9-million award from the NCI to serve as a Lead Academic Participating Site for the newly created network, to provide scientific leadership in development and conduct of clinical trials in association with the adult clinical trial groups.
“Our cancer center has a well-deserved reputation for high-impact clinical research and a deep and long-standing commitment to the former cancer cooperative groups that now comprise the NCTN,” said Hedy Kindler, MD, associate professor of medicine at the University of Chicago and lead principal investigator for the Chicago site. “This grant will enable us to provide outstanding multidisciplinary scientific and administrative leadership in the design and implementation of innovative and potentially practice-changing clinical trials within the NCTN.”